Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
FibroGen (FGEN) Stock Price & Analysis
896 Followers
FGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.33 - $19.47
Previous Close$1.15
Volume1.04M
Average Volume (3M)2.12M
Market Cap
$114.40M
Enterprise Value$73.33M
Total Cash (Recent Filing)$235.59M
Total Debt (Recent Filing)$152.55M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 05, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding99,475,398
10 Day Avg. Volume1,349,222
30 Day Avg. Volume2,117,918
Standard Deviation0.29
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.57
Price to Sales (P/S)4.21
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit0.57
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$2.00Price Target Upside73.91% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
FibroGen News
PremiumMarket News
3 Penny Stocks to Watch Now
PremiumPre-Earnings
FibroGen (FGEN) Q1 Earnings Cheat SheetBulls Say, Bears Say
Bulls Say
Financial HealthThe company concluded the quarter with a robust cash position, ensuring operational funding for multiple future years.
Product Sales GrowthSales of Evrenzo (roxadustat) in China grew significantly, driven by an impressive volume increase.
Upcoming CatalystsAnticipation builds as the company prepares to announce multiple updates from its promising oncology pipeline.
Bears Say
Drug EfficacyConsensus estimates continue to imply low probability of success for pamrevlumab in pancreatic cancer.
Financial Performance4Q23 total product revenue of $23.5 million, below Visible Alpha consensus of $28.6 million and Goldman Sachs estimate of $29.8 million.
Product SalesRoxadustat sales higher year-over-year but pricing cuts blunt solid volume growth.
---
Ownership Overview
7.29% Insiders
29.58% Mutual Funds
38.80% Other Institutional Investors
24.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $0.33 and its highest was $19.47 in the past 12 months.
What is FibroGen’s market cap?
Currently, no data Available
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Aug 05, 2024 which is in 66 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on May 06, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.418 by $0.088.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -$0.32.
How many shares outstanding does FibroGen have?
FibroGen has 99,475,395 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.418. Following the earnings report the stock price went up 18.103%.
Which hedge fund is a major shareholder of FibroGen?
Among the largest hedge funds holding FibroGen’s share is PRIMECAP Management Co. It holds FibroGen’s shares valued at 34M.
---
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$2.00 (73.91% Upside)
$2.00 (73.91% Upside)
Blogger Sentiment
Neutral
FGEN Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 83.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $95.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-93.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.06%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
---
FGEN Company Deck
---
FGEN Earnings Call
Q1 2024
0:00 / 0:00
---
FGEN Stock 12 Month Forecast
Average Price Target
$2.00
▲(73.91% Upside)
Technical Analysis
Best Analysts Covering FGEN
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+16.56%
reiterated a sell rating 26 days ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +16.56% per trade.
---